Ann Cabot, DO
Neurology · Manchester, NHNPI 1912018201
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $473,283 of the $622,198 with a category attached, or 76.1%. 17 manufacturers reported payments, led by EMD Serono, Inc. at 24.8% of the total. Among neurology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 601 payments — averaging $1035.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$154K
- TG Therapeutics, Inc.$127K
- Biogen$95K
- Sanofi$50K
- Genentech USA, Inc.$45K
- E.r. Squibb & Sons, L.L.C.$37K
- plus $113K from 11 others
What the payments were for
- Consulting fees$113,80418%
- Speaking & faculty fees$473,28376%
- Travel & lodging$21,9754%
- Food & beverage$12,5432%
- Education$5920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 117 | $154,424 |
| TG Therapeutics, Inc. | 78 | $126,842 |
| Biogen | 116 | $95,270 |
| Sanofi | 49 | $50,367 |
| Genentech USA, Inc. | 38 | $45,164 |
| E.r. Squibb & Sons, L.L.C. | 27 | $36,885 |
| Bristol Myers Squibb | 46 | $36,409 |
| Novartis | 26 | $30,219 |
| Novartis Pharma AG | 3 | $13,599 |
| AstraZeneca | 12 | $10,677 |
| Teva Pharmaceuticals USA, Inc. | 6 | $8,549 |
| Amgen(2 entities) | 60 | $7,375 |
| Genentech, Inc. | 5 | $6,026 |
| AbbVie | 14 | $306 |
| Sanofi-aventis U.S. LLC | 1 | $66 |
| Pfizer | 1 | $16 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$622,198 in reported general payments places this provider in the 95th percentile of 92 neurology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 91 | $827,926 |
| TecfideraDimethyl Fumarate | 23 | $207,780 |
| CopaxoneGlatiramer Acetate | 34 | $195,229 |
| AubagioTeriflunomide | 18 | $183,400 |
| AmpyraDalfampridine | 12 | $145,187 |
| Plegridy PenPeginterferon Beta-1a | 12 | $98,448 |
| Avonex (4 Pack)Interferon Beta-1a | 11 | $89,866 |
| Glatiramer Acetate | 35 | $71,649 |
| Dalfampridine ErDalfampridine | 78 | $36,804 |
| Teriflunomide | 92 | $33,329 |
| Dimethyl Fumarate | 23 | $19,703 |
| QuliptaAtogepant | 14 | $16,989 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $10,817 |
| Baclofen | 350 | $9,991 |
| Modafinil | 76 | $9,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Avonex (4 Pack) | $95,270 | $297,64634 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $8,549 | $195,22934 claims |
| SanofiAubagio | $50,367 | $183,40018 claims |
| AbbVieQulipta | $306 | $16,98914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 neurology providers in New Hampshire.
Other neurology in Manchester
- Adnan KhanManchester$3K
- Emilia RaimondoManchester$791
- Jing JiManchester$500
- Jason FlemingManchester$495
- Anas HannounManchester$414
- Ana LizamaManchester$326
- Xiao Qing WangManchester$306
- Elena IvashinaManchester$301
- Keith McAvoyManchester$236
- Oliver PhillipsLebanon$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.